Evaluation of the new AxSYM cyclosporine assay: Comparison with TDx monoclonal whole blood and emit cyclosporine assays

Clinical Chemistry

Volumn 45, Issue 3, 1999, Pages 432-435

  Wallemacq, Pierre E ^a   Alexandre, Kathy ^b  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b Abbott Immunology   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN;

ARTICLE; BLOOD ANALYSIS; CROSS REACTION; DRUG DETERMINATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; QUANTITATIVE DIAGNOSIS;

EID: 0032912183     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/45.3.432     Document Type: Article

References (15)

1. 1. Yee GC, Salomon DR. Cyclosporine. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied pharmacokinetics. Principles of therapeutic drug monitoring. 3rd ed. Vancouver, WA: Applied Therapeutics Inc., 1992;28:1-40.
2. 2. Gerson B. Cyclosporine controversies [Review]. Clin Lab Med 1987;7:669-86.
3. 3. Oellerich M, Armstrong VW, Kahan B, Shaw L, Holt DW, Yatscoff R, et al. Lake Louise consensus conference on cyclosporine monitoring in organ transplantation: report of the consensus panel. Ther Drug Monit 1995;17: 642-54.
4. 4. Maurer G, Lemaire M. Biotransformation of cyclosporine and blood distribution of its metabolites. Transplant Proc 1986;6(Suppl 5):25-34.
5. 5. Donatsch P, Abisch E, Homberger M, Traber R, Trapp M, Voges R. A radioimmunoassay to measure cyclosporine A in plasma and serum samples. J Immunoassay 1981;2:19-32.
6. 6. Chan GL, Weinstein SS, LeFor WW, Spoto E, Kahana L, Shires DL. Relative performance of specific and nonspecific fluorescence polarization immunoassay for cyclosporine in transplant patient. Ther Drug Monit 1992;14:42-7.
7. 7. Copeland KR, Yatscoff RW. Immunosuppressive activity and toxicity of cyclosporine metabolites characterized by mass spectroscopy and nuclear magnetic resonance. Transplant Proc 1990;22:1146-9.
8. 8. Copeland KR, Yatscoff RW, Mc Kenna R. Immunosuppressive activity of cyclosporine metabolites compared and characterized by mass spectroscopy and nuclear magnetic resonance. Clin Chem 1990;36:225-9.
9. 9. Donatsch P, Rickenbacher U, Ryffel B, Brouillard J-F. Sandimmune metabolites: the potential to cause adverse reactions in the rat. Transplant Proc 1990;22:1137-40.
10. 10. Consensus document. Hawk's Cay meeting on therapeutic drug monitoring of cyclosporine. Transplant Proc 1990;22:1357-61.
11. 11. Lindholm A, Henricsson S, Groth CG, Sjöqvist F. A prospective study of cyclosporine concentration in relation to its therapeutic effect and toxicity after renal transplantation. Br J Clin Pharmacol 1990;30:443-52.
12. 12. Holt DW, Marsden JT, Johnston A. Measurement of cyclosporine: methodological problems. Transplant Proc 1986;18(Suppl 5):101-10.
13. 13. Yatscoff RW, Copeland KR, Faraci CJ. Abbott TDx monoclonal antibody assay evaluated for measuring cyclosporine in whole blood. Clin Chem 1990;36: 1969-73.
14. 14. Beresini MH, Davalian D, Alexander S, Toton-Quinn R, Barnett B, Cerelli MJ, et al. Evaluation of EMIT cyclosporine assay for use with whole blood. Clin Chem 1993;39:2235-41.
15. 15. Holt DW, Johnston A. Cyclosporin A: analytical methodology and factors affecting therapeutic drug monitoring. Ther Drug Monit 1995;17:625-30.